Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This transcript is a natural antisense RNA discovered in the vicinity of the STOM gene. Natural antisense transcripts (NATs) such as antisense STOM are increasingly recognized as pervasive throughout the genome, where they play roles in the regulation of gene expression, chromatin structure, and epigenetic marking[4][1][5]. Their functional mechanisms may include modulation of transcriptional dynamics, epigenetic remodeling, and even interference with the paired sense (protein-coding) genes' expression[1][3]. While some antisense transcripts have been associated with disease states or prognosis—especially in cancer or imprinting contexts—their individual roles are often gene- and context-specific, and direct drug targeting remains largely unexplored[3][5]. As a noncoding RNA, novel transcript, antisense STOM is not considered a classical drug target, receptor, enzyme, or protein biomarker.
No direct mechanism applicable; NATs sometimes modulate gene expression by chromatin remodeling or RNA pairing[5]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense STOM.